Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

Bente Arboe; Maja Halgren Olsen; Anne Katrine Duun-Henriksen; Jette Sønderskov Gørløv; Kristina Fruerlund Nielsen; Rasmus Heje Thomsen; Charlotte Madsen; Søren Ramme Nielsen; Susanne Oksbjerg Dalton; Peter de Nully Brown

doi:10.1080/10428194.2017.1369061

Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

Bente Arboe^*, Maja Halgren Olsen, Anne Katrine Duun-Henriksen, Jette Sønderskov Gørløv, Kristina Fruerlund Nielsen, Rasmus Heje Thomsen, Charlotte Madsen, Søren Ramme Nielsen, Susanne Oksbjerg Dalton, Peter de Nully Brown

^*Corresponding author for this work

Department of Clinical Medicine

2 Citations (Scopus)

Abstract

In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox’s proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.

Original language	English
Journal	Leukemia and Lymphoma
Volume	59
Issue number	5
Pages (from-to)	1153-1162
ISSN	1042-8194
DOIs	https://doi.org/10.1080/10428194.2017.1369061
Publication status	Published - 2018

Keywords

lymphoma and Hodgkin disease
prognostication
Transplant toxicity

Access to Document

10.1080/10428194.2017.1369061

Fingerprint

Dive into the research topics of 'Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation'. Together they form a unique fingerprint.

Cite this

Arboe, B., Halgren Olsen, M., Duun-Henriksen, A. K., Gørløv, J. S., Nielsen, K. F., Thomsen, R. H., Madsen, C., Nielsen, S. R., Dalton, S. O., & Brown, P. D. N. (2018). Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 59(5), 1153-1162. https://doi.org/10.1080/10428194.2017.1369061

Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. / Arboe, Bente; Halgren Olsen, Maja; Duun-Henriksen, Anne Katrine et al.
In: Leukemia and Lymphoma, Vol. 59, No. 5, 2018, p. 1153-1162.

Research output: Contribution to journal › Journal article › Research › peer-review

Arboe, B, Halgren Olsen, M, Duun-Henriksen, AK, Gørløv, JS, Nielsen, KF, Thomsen, RH, Madsen, C, Nielsen, SR, Dalton, SO & Brown, PDN 2018, 'Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation', Leukemia and Lymphoma, vol. 59, no. 5, pp. 1153-1162. https://doi.org/10.1080/10428194.2017.1369061

Arboe B, Halgren Olsen M, Duun-Henriksen AK, Gørløv JS, Nielsen KF, Thomsen RH et al. Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Leukemia and Lymphoma. 2018;59(5):1153-1162. doi: 10.1080/10428194.2017.1369061

Arboe, Bente ; Halgren Olsen, Maja ; Duun-Henriksen, Anne Katrine et al. / Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 5. pp. 1153-1162.

@article{cf614704bfcf48d4a3bb1693fd005e2f,

title = "Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation",

abstract = "In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox{\textquoteright}s proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.",

keywords = "lymphoma and Hodgkin disease, prognostication, Transplant toxicity",

author = "Bente Arboe and {Halgren Olsen}, Maja and Duun-Henriksen, {Anne Katrine} and G{\o}rl{\o}v, {Jette S{\o}nderskov} and Nielsen, {Kristina Fruerlund} and Thomsen, {Rasmus Heje} and Charlotte Madsen and Nielsen, {S{\o}ren Ramme} and Dalton, {Susanne Oksbjerg} and Brown, {Peter de Nully}",

year = "2018",

doi = "10.1080/10428194.2017.1369061",

language = "English",

volume = "59",

pages = "1153--1162",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

AU - Arboe, Bente

AU - Halgren Olsen, Maja

AU - Duun-Henriksen, Anne Katrine

AU - Gørløv, Jette Sønderskov

AU - Nielsen, Kristina Fruerlund

AU - Thomsen, Rasmus Heje

AU - Madsen, Charlotte

AU - Nielsen, Søren Ramme

AU - Dalton, Susanne Oksbjerg

AU - Brown, Peter de Nully

PY - 2018

Y1 - 2018

N2 - In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox’s proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.

AB - In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox’s proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.

KW - lymphoma and Hodgkin disease

KW - prognostication

KW - Transplant toxicity

U2 - 10.1080/10428194.2017.1369061

DO - 10.1080/10428194.2017.1369061

M3 - Journal article

C2 - 28868963

AN - SCOPUS:85028870852

SN - 1042-8194

VL - 59

SP - 1153

EP - 1162

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -